HILPDA unveiled as therapeutic target in renal cell carcinoma
Feb. 21, 2024
MYC oncogene is known to be amplified in 5% to 10% and overexpressed in 20% of clear cell renal cell carcinoma (ccRCC), conferring aggressiveness. Researchers have now found...